HLA‐DR is often considered an activation marker for T cells.[24] Paradoxically, HLA‐DR+CD8+T cells we categorized in the context did elevate in peripheral blood from non‐responders before treatment, whereas such clusters in situ tumors may be beneficial for therapy, as also validated by the TCGA external HCC cohort. The gene discussed is CD8A; the disease is hepatocellular carcinoma.